Uncategorized – DiNAQOR

DiNAQOR Congratulates Siegfried and DINAMIQS on Successful Completion of their State-of-the-Art cGMP Facility for Viral Vectors

September 29, 2025 by Andrew Hartmann

Zurich, September 29, 2025 – DiNAQOR AG, a global advanced medicines company builder, today congratulated Siegfried (SIX: SFZN) and its subsidiary DINAMIQS on the successful completion and inauguration of their new cGMP viral vector manufacturing facility in Switzerland. DINAMIQS was established in 2022 and spun out from DiNAQOR as an independent entity in 2023. Since … Read more

DiNAQOR partners with Siegfried to scale and commercialize DiNAMIQS as a best-in-class development and manufacturing platform for cell and gene therapies

May 4, 2023 by Andrew Hartmann

ZURICH-SCHLIEREN, Switzerland, May 4, 2023 – DiNAQOR, an innovative genetic medicine company headquartered in Switzerland with subsidiaries in Laguna Hills/California/USA and Hamburg/Germany focused on proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies and other therapeutics, today announced that it will sell a 95% stake in its subsidiary DiNAMIQS to … Read more

DiNAQOR Appoints Two Seasoned Executives to Leadership Team

January 9, 2023 by admindqor

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth

DiNAQOR to Participate in Several Fall Conferences

September 20, 2022September 19, 2022 by admindqor

Dinaqor is pleased to announce our participation in several fall conferences.

DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients

May 16, 2022 by admindqor

DiNAQOR announced the launch of DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, that will accelerate development timelines and reduce costs and risk for genetic medicine companies bringing new treatments to market.

DiNAQOR Announces Research Collaboration with Children’s Medical Research Institute to Develop Novel, Cardiac Specific Capsids

January 10, 2022 by admindqor

DiNAQOR has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop novel bioengineered adeno-associated virus (AAV) capsids to route gene therapy directly to human cardiac muscle.

DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production

September 23, 2021 by admindqor

DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices.